Integer Holdings Co. (NYSE:ITGR) Given Average Rating of “Moderate Buy” by Analysts

Integer Holdings Co. (NYSE:ITGR) has received a consensus recommendation of “Moderate Buy” from the nine analysts that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $145.44.

ITGR has been the subject of a number of recent analyst reports. KeyCorp raised their price target on Integer from $139.00 to $144.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 15th. Benchmark boosted their price target on shares of Integer from $130.00 to $140.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Piper Sandler restated an “overweight” rating and issued a $140.00 price objective (up from $125.00) on shares of Integer in a report on Friday, October 25th. Truist Financial raised their target price on Integer from $147.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Finally, Citigroup increased their price objective on Integer from $130.00 to $145.00 and gave the stock a “neutral” rating in a report on Wednesday, December 11th.

Integer Stock Up 0.3 %

Shares of NYSE ITGR opened at $140.91 on Tuesday. The company has a market cap of $4.73 billion, a price-to-earnings ratio of 43.49, a PEG ratio of 1.70 and a beta of 1.12. The company has a quick ratio of 2.09, a current ratio of 3.28 and a debt-to-equity ratio of 0.67. The firm’s fifty day moving average is $136.53 and its 200 day moving average is $128.87. Integer has a 52 week low of $94.56 and a 52 week high of $142.76.

Integer (NYSE:ITGR) last issued its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $1.43 EPS for the quarter, beating the consensus estimate of $1.36 by $0.07. The firm had revenue of $431.42 million during the quarter, compared to the consensus estimate of $440.59 million. Integer had a net margin of 6.70% and a return on equity of 11.63%. The company’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.27 earnings per share. On average, equities research analysts expect that Integer will post 5.33 earnings per share for the current year.

Hedge Funds Weigh In On Integer

A number of hedge funds have recently added to or reduced their stakes in the company. Contravisory Investment Management Inc. boosted its holdings in Integer by 55.9% in the third quarter. Contravisory Investment Management Inc. now owns 223 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 80 shares during the last quarter. HighTower Advisors LLC grew its holdings in shares of Integer by 0.8% in the third quarter. HighTower Advisors LLC now owns 12,041 shares of the medical equipment provider’s stock worth $1,579,000 after acquiring an additional 90 shares during the period. Xponance Inc. increased its position in Integer by 4.9% during the second quarter. Xponance Inc. now owns 2,112 shares of the medical equipment provider’s stock valued at $245,000 after acquiring an additional 99 shares during the last quarter. Azzad Asset Management Inc. ADV lifted its holdings in Integer by 0.9% in the third quarter. Azzad Asset Management Inc. ADV now owns 11,572 shares of the medical equipment provider’s stock valued at $1,504,000 after acquiring an additional 107 shares during the period. Finally, Versant Capital Management Inc boosted its position in Integer by 98.4% in the fourth quarter. Versant Capital Management Inc now owns 369 shares of the medical equipment provider’s stock worth $49,000 after purchasing an additional 183 shares during the last quarter. 99.29% of the stock is currently owned by hedge funds and other institutional investors.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.